Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Intraoperative Radiotherapy
Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal
Intraoperative Radiotherapy ( Dr Mahima Pant - National Academy for Medical Sciences (NAMS), Kathmandu, Nepal )
25 Sep 2022
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced br...
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022
Cancer survivors' stories: An African perspective
Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation
Cancer survivors' stories: An African perspective ( Dr Zainab Shinkafi-Bagudu - Founder of the Medicaid Cancer Foundation )
15 Sep 2022
ESMO 2022: Breast and ovarian trial analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim ...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast can...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-ne...
Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands
Nivolumab and ipilimumab with tumour-infiltrating lymphocytes to treat triple-negative breast cancer ( Dr Iris Nederlof - The Netherlands Cancer Institute, Amsterdam, Netherlands )
12 Sep 2022
A new era of early cancer detection with blood test may change cancer screening ...
Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA
A new era of early cancer detection with blood test may change cancer screening paradigms ( Dr Deb Schrag, Memorial Sloan Kettering Cancer Center, New York, USA )
11 Sep 2022
New era of early cancer detection blood tests on the horizon
Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA
New era of early cancer detection blood tests on the horizon ( Dr Deborah Schrag - Memorial Sloan Kettering Cancer Center, New York City, USA )
11 Sep 2022
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and...
Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Franc...
Sacituzumab govitecan continues to improve OS for ET-resistant HR+/HER2-mBC, and QoL update ( Prof Hope Rugo - UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA )
11 Sep 2022